Results 41 to 50 of about 284,370 (314)

Cardiac Safety of Trastuzumab on 185 Patients with HER2 Positive Breast Cancer

Zhongliu Fangzhi Yanjiu, 2018
Objective To analyze the cardiac safety of trastuzumab on HER2 positive breast cancer patients. Methods Trastuzumab was administrated every three weeks in 185 patients with HER2 positive breast cancer.
MENG Wenjing, ZHANG Jibo, LI Shufen, TONG Zhongsheng   +3 more
doaj   +1 more source

Nanobody based dual specific CARs [PDF]

, 2018
Recent clinical trials have shown that adoptive chimeric antigen receptor (CAR) T cell therapy is a very potent and possibly curative option in the treatment of B cell leukemias and lymphomas.
Abken, Hinrich, Bonte, Sarah, De Munter, Stijn, Goetgeluk, Glenn, Ingels, Joline, Kerre, Tessa, Pille, Melissa, Vandekerckhove, Bart, Weening, Karin   +8 more
core   +2 more sources

HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer [PDF]

Clinical Cancer Research, 2017
Abstract Purpose: Resistance to anti-HER2 therapies in HER2+ breast cancer can occur through activation of alternative survival pathways or reactivation of the HER signaling network. Here we employed BT474 parental and treatment-resistant cell line models to investigate a mechanism by which HER2+ breast cancer can reactivate the HER ...
Xu X., De Angelis C., Burke K. A., Nardone A., Hu H., Qin L., Veeraraghavan J., Sethunath V., Heiser L. M., Wang N., Ng C. K. Y., Chen E. S., Renwick A., Wang T., Nanda S., Shea M., Mitchell T., Rajendran M., Waters I., Zabransky D. J., Scott K. L., Gutierrez C., Nagi C., Geyer F. C., Chamness G. C., Park B. H., Shaw C. A., Hilsenbeck S. G., Rimawi M. F., Gray J. W., Weigelt B., Reis-Filho J. S., Osborne C. K., Schiff R.   +33 more
openaire   +3 more sources

Cutaneous Adnexal Adenocarcinoma: Genomic Analysis and Successful HER2-targeted Therapy of Metastatic Disease

Acta Dermato-Venereologica, 2023
is missing (Short communication)
Yui Hirano-Lotman, Yoshihiro Ishida, Yuichiro Endo, Seishi Ogawa, Kenji Kabashima   +4 more
doaj   +1 more source

DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. [PDF]

, 2017
Veliparib combined with carboplatin (VC) was an experimental regimen evaluated in the biomarker-rich neoadjuvant I-SPY 2 trial for breast cancer. VC showed improved efficacy in the triple negative signature.
Berry, Don, Brown-Swigart, Lamorna, Buxton, Meredith, DeMichele, Angela, Esserman, Laura, Glas, Annuska, Hirst, Gillian, Hylton, Nola, Linn, Sabine, Olopade, Olufunmilayo, Paoloni, Melissa, Petricoin, Emanuel, Rugo, Hope, Sanil, Ashish, Severson, Tesa M, Symmans, Fraser, van 't Veer, Laura, Wolf, Denise M, Wulfkuhle, Julia, Yau, Christina, Yee, Doug   +20 more
core   +2 more sources

Age-related Variation in Expression of Breast Cancer Tumour Markers in Iranian Patients [PDF]

Middle East Journal of Cancer, 2021
Background: There are believed to be several risk factors affecting the prognosis of breast cancer through their effect on the growth rate of tumour.
Fatemeh Homaei Shandiz, Fahimeh Afzaljavan, Amir Tajbakhsh, Maryam Rivadeh, Nourieh Sharifi, Mohammad Taghi Shakeri, Alireza Pasdar   +6 more
doaj   +1 more source

Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC) [PDF]

, 2005
Background: The aim of this retrospective analysis was to evaluate the impact of trastuzumab-based regimens on the survival of patients with HER2-overexpressing metastatic breast cancer (MBC).
Baselga J, Baselga J, Cobleigh MA, Gelmon KA, Kaplan EL, Marty M, Robert NJ, Slamon D, Tripathy D, Vogel CL   +9 more
core   +1 more source

Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary [PDF]

, 2018
Breast Cancer (BC) skin metastases represent a challenging clinical scenario. Although they usually arise when other distant metastases are already present, they may also represent a form of locoregional recurrence (LRR). Systemic therapy in this setting
Dieci, Maria V, Evangelista, Laura, Giarratano, Tommaso, Giorgi, Carlo A, Guarneri, Valentina, Michieletto, Silvia, Miglietta, Federica, Polico, Ilaria, Tsvetkova, Vassilena   +8 more
core   +1 more source

Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy [PDF]

, 2014
The receptor tyrosine kinases (RTKs) are key drivers of cancer progression and targets for drug therapy. A major challenge in anti-RTK treatment is the dependence of drug effectiveness on co-expression of multiple RTKs which defines resistance to single ...
Bown, James L., Deeni, Yusuf Y., Goltsov, Alexey, Harrison, David J., Hu, Huizhong, Khalil, Hilal S., Kyriakidis, Stylianos, Langdon, Simon P., Soininen, Tero   +8 more
core   +6 more sources

The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab

Biomolecules, 2019
G309 or S310 mutations on the HER2 extracellular domain II induce receptor activation. Clinically, S310F is most frequent among HER2 extracellular domain mutations and patients with the S310F mutation without HER2 amplification responded to trastuzumab ...
Jung Won Shin, Soohyun Kim, Suji Ha, Byungsan Choi, Seongyeong Kim, Seock-Ah Im, Tae-Young Yoon, Junho Chung   +7 more
doaj   +1 more source